Background: 170 million persons worldwide are infected with hepatitis C, many of whom are undiagnosed. Although rapid diagnostic tests (RDTs) and point-of-care tests (POCTs) provide a time-and cost-saving alternative to conventional laboratory tests, their global uptake partly depends on their performance.
T
he World Health Organization estimates (1) that 170 million persons worldwide are infected with the hepatitis C virus (HCV). Developing countries in Africa and Asia report the highest prevalence of this virus, which is transmitted predominantly by unscreened blood transfusions, injection drug use, and unsafe therapeutic injections (2) . Because HCV and HIV infections share similar routes of transmission, about 40% of HIV-infected persons are co-infected with HCV (3) . The prevalence of HIV-HCV co-infection varies from 16% to 33% in injection drug users in North America to 50% in Brazil (2, 4) . Morbidity and mortality are also higher in co-infected populations (5) (6) (7) (8) . Chronic hepatitis C infection is associated with long-term complications, such as liver fibrosis, cirrhosis, and hepatocellular carcinoma (1) . Although newer treatments for hepatitis C (such as telaprevir or boceprevir with pegylated interferon and ribavirin) have made viral suppression a possibility, timely screening is critical to the success of these newer treatments (9) . In addition to the high burden of co-infection, marginalized at-risk populations face social, structural, and economic barriers, such as limited access to testing (10) and lapses in health insurance (11) , which hamper early screening and timely engagement with care. The situation is worse in global low-resource settings, where standardized laboratory tests are expensive and often not covered by public health systems-and thus are rarely performed or offered on-site or in time, leading to suboptimal care and screening.
In the United States, the Centers for Disease Control and Prevention (CDC) recommends using an enzyme immunoassay (EIA) and either recombinant immunoblot assay or HCV nucleic acid testing for RNA to diagnose hepatitis C infection (12) . Although this algorithm effectively detects active infection, the tests are expensive and have long turnaround times. Convenient, quality-assured, antibody-based rapid diagnostic tests (RDTs) and pointof-care tests (POCTs) could facilitate preliminary screening, although they cannot differentiate between acute and chronic infections. Their rapid turnaround time limits loss to follow-up and facilitates early linkages. Although both diagnostic test types are rapid, RDTs require special equipment, such as centrifuges and refrigerators, whereas POCTs eliminate the need for electricity and are more robust at high temperatures, thus offering additional opportunities to expand screening (13) .
Several POCTs are in use, including the OraQuick HCV Rapid Antibody Test (OraSure Technologies, Bethlehem, Pennsylvania), Anti-HCV Ab rapid test (Tema Ricerca, Bologna, Italy), SM-HCV Rapid Test (SEROMed Labor Spezialitaten, Pollenfeld, Germany), Dual Path Platform test (Chembio Diagnostic Systems, Medford, New York), Multiplo Rapid HIV/HCV Antibody Test (MedMira, Halifax, Nova Scotia, Canada), SD Bioline HCV (Standard Diagnostics, Yongin, Korea), Bioeasy HCV Test (Bioeasy Diagnóstica, Belo Horizonte, Minas Gerais, Brazil), Hexagon HCV (Human Diagnostics Worldwide, Wiesbaden, Germany), and Genedia HCV Rapid LF (Green Cross Medical Science, Yongin, Korea). The RDTs on the market include the Diagnos HCV BiDot (J. Mitra, New Delhi, India), HCV Tri-Dot (J. Mitra), Advanced Quality One Step HCV Test (Bionike, San Francisco, California), SeroCard HCV (Trinity Biotech, Bray, Ireland), and HCV Spot (MP Biomedicals, Santa Ana, California).
In 2010, the U.S. Food and Drug Administration approved the OraQuick HCV Rapid Antibody Test and granted a waiver from the Clinical Laboratory Improvements Amendments of 1988 to allow its use in nontraditional settings. This offered the potential to increase HCV screening into hitherto untapped domains.
Given the high absolute burden of HIV-HCV coinfection in marginalized populations (such as injection drug users) in North America and Europe, the high prevalence of HCV mono-infection in Africa and Asia (2) , and the high costs of conventional serologic tests, introducing and integrating HCV RDTs and POCTs into mandated HIV programs may lead to cost savings and expedited firstline screening of at-risk populations. Global public health agencies are interested in knowing the diagnostic performance of these tests but, to our knowledge, this evidence has not been synthesized. To address this knowledge gap, we reviewed evidence on the diagnostic performance of globally available RDTs and POCTs to screen for hepatitis C.
METHODS
We reviewed the diagnostic accuracy variables (sensitivity, specificity, likelihood ratios [LRs] , and diagnostic odds ratios [DORs]) of available RDTs and POCTs that screen for hepatitis C in oral fluid, whole blood, serum, or plasma specimens. We evaluated studies conducted worldwide in adults (aged Ն18 years), regardless of their risk profile, in all study settings (laboratory-or field-based) and all study designs (cross-sectional studies and case-control or serum panel assessments). We followed PRISMA (Preferred Reporting Items for Systematic Reviews and MetaAnalyses) guidelines in reporting the synthesis.
Data Sources and Searches
We searched MEDLINE (via PubMed), EMBASE (via Ovid), BIOSIS, and Web of Science from 1992 to OR "rapid test" OR "rapid assay"). We used similar search strings for the other 3 databases. We also searched bibliographies of included articles for studies missed by the original search.
Study Selection
We included studies conducted in adults, both abstracts and full-text articles, if they provided enough raw data to recreate the 2 ϫ 2 diagnostic tables. We did not exclude articles on the basis of study location, language of publication, or study design. However, we excluded studies on prevalence or the accuracy of laboratory-based tests, those missing relevant information on the index test (such as type [RDT or POCT] or manufacturer), manufacturer reports, and package inserts. We did not include manufacturer reports because they provide inadequate details on study conduct; have overt conflicts of interest; often provide accuracy estimations without CIs; and exclude important methodological details on study design, patient populations, and samples. The Two reviewers independently conducted the searches and screened articles for eligibility. After initial identifica- tion of all studies and deletion of duplicates, we did a preliminary screening of 10 026 articles based on title and abstract. Of these, 52 were considered for full-text review, of which 12 were included in the study. A hand-search of the bibliographies of included articles yielded 7 more articles, for a total of 19 eligible studies.
Data Extraction and Quality Assessment
Two reviewers independently abstracted data using a prepiloted form and critiqued the quality of the studies, with a third reviewer contacted in case of disagreement. We consulted authors when the 2 ϫ 2 tables were missing data or the study method was unclear.
We extracted data on the characteristics of the study population, including sampling strategies (purposive or consecutive random sampling), risk for hepatitis C as defined by the authors, sample size, inclusion and exclusion criteria, specimen tested (oral fluid, whole blood, serum, or plasma), whether the test was an RDT or a POCT, reference standard, funding sources, and any reported conflicts of interest. We also extracted raw data-numbers of truepositive, true-negative, false-positive, and false-negative results-and items necessary to assess study quality.
Tests that were easy to use (such as those with no need for sample processing), were robust at higher temperatures, and had a long shelf life (Ͼ6 months) were considered POCTs. We defined RDTs as those requiring sample processing and refrigerators for storage. Both RDTs and POCTs had to be performed in less than 30 minutes.
We classified reference standards as perfect or imperfect on the basis of CDC recommendations; EIA and recombinant immunoblot assay or EIA and nucleic acid testing were classified as perfect, whereas all other algorithms (such as EIA alone) were classified as imperfect.
We assessed the methodological and reporting quality of studies by using the QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies 2) tool (14) and the STARD (Standards for the Reporting of Diagnostic Accuracy Studies) checklists (15) , giving equal weight to all items. The QUADAS-2 checklist assessed potential bias in studies with respect to patient selection, index test, reference test, and patient flow (14) . In assessing the quality of studies, we also focused on reference standards used and any reported conflict of interest.
Data Synthesis and Analysis
We did all statistical analyses in Intercooled Stata, version 9 (StataCorp, College Station, Texas).
For our meta-analysis of estimates of accuracy, we used the bivariate model, which assumes that the measures of sensitivity and specificity from a study are negatively correlated and that the logit transformations of sensitivity and specificity have a bivariate normal distribution (16) . We calculated the sensitivity, specificity, positive LR, negative LR, and DOR. The Appendix (available at www.annals .org) defines the diagnostic accuracy measures used in this study. The LRs of a test inform the pretest probability of disease and provide a posttest probability. A positive LR higher than 5 and a negative LR less than 0.2 provide strong diagnostic evidence (17) .
Before meta-analysis, we stratified studies into 4 subgroups based on the specimen tested and whether the test was a POCT or an RDT. Because data were insufficient for all tests and all of the tests under investigation were antibody-based, we stratified evidence into 4 subgroups on the same basis: POCTs of serum or plasma, POCTs of whole blood or finger-stick blood, RDTs of serum or plasma, and POCTs of oral fluid.
Role of Funding Source
Our study was funded by the Canadian Institutes of Health Research. The funding source had no role in the conception, design, or conduct of the review. The investi- 
RESULTS

Characteristics of Studies
Table 1 (18 -32) shows the study characteristics. A total of 19 studies were reviewed, of which only 18 could be meta-analyzed. One study (18) , which reported a sensitivity of 0% and specificity of 100% with no reasonable explanations, was excluded from the quantitative analysis.
The 18 pooled studies contributed 38 data points (Appendix Table 1 , available at www.annals.org). Some studies contributed additional data points by comparing the accuracy of 2 or more tests (19, 20) , reporting data from multiple study sites (20), or reporting the accuracy of a test in more than 1 type of specimen (20 -22) .
Of the 19 total studies, 11 (58%) were conducted in developing settings (5, 6, 18, (23) (24) (25) (26) (27) (28) (29) (30) . Sample sizes ranged from 60 to 2754 persons. Table 2 lists the index test characteristics.
Study Quality
The quality of study reporting ranged from poor to good (STARD scores from 8 to 20 of 25) ( Table 3) . Twelve studies (63%) (5-7, 11, 19 -22, 27-29, 31) were cross-sectional, and the remainder were case-control studies (assessed by the QUADAS-2 checklist). Only 3 studies (16%) (7, 29, 32 ) reported blinding of test readers, whereas 1 explicitly reported lack of blinding (22) . Nine studies (47%) (11, 19 -25, 32 ) used a CDC-recommended reference standard (EIA and recombinant immunoblot assay), whereas the remaining 10 studies used only 1 test (EIA, microenzyme immunoassay, or chemiluminescent immunoassay) as the reference standard. All of the research groups administered the same reference test to all patients, thus avoiding partial or differential verification bias.
Four studies (21%) (11, 21, 30, 32) reported a financial relationship with or received funding from industry, 6 (32%) (5, 7, 18, 22, 26, 27) omitted disclosure of conflicts of interest, 1 (28) explicitly declared no conflict of interest, 3 (23-25) were independent evaluations from the World Health Organization, and 5 (6, 19, 20, 29, 31) reported receiving tests in kind from manufacturers but no conflict of interest. Table 1 reports estimates of sensitivity and specificity from each study. Appendix Table 1 reports the raw data. 
Results Pooled by Subgroup
DISCUSSION
Our meta-analysis suggests that POCTs of blood (serum, plasma, or whole blood) have the highest accuracy, followed by RDTs of serum or plasma and then by POCTs of oral fluids. However, all subgroups showed high positive LRs, low negative LRs, and high DORs; the best LRs and DORs were reported for POCTs of serum and plasma, followed by those of whole blood, RDTs of serum and plasma, and POCTs of oral fluids. When sensitivity and specificity are similar, interpretation of the LR and DOR of the test influences conclusive changes from pretest to posttest probability of hepatitis C infection (17) . Given the convenience of POCTs and their rapid turnaround time, these results show great potential for expanded first-line screening for hepatitis C infection and demonstrate the utility of blood-based singleton POCTs and of multiplex POCTs designed to provide integrated HIV and HCV screening of at-risk populations.
The high positive and low negative LRs found in each subgroup, especially those that tested serum, plasma, and whole blood, also imply that RDTs and POCTs can meaningfully inform the posttest probability of infection. The pooled accuracies of these tests have implications for their use in clinical and nonclinical outreach settings. For example, POCTs of oral fluids showed a slightly higher falsenegative rate than POCTs of whole blood or finger-stick blood, which could be due to the lower concentration of antibodies or the weaker binding in oral fluid than in blood samples (33) . The false-negative rate is of particular concern in high-risk groups, in which a high rate is more likely to lead to an undetected infection. In such scenarios, timely confirmatory testing could resolve a preliminary screening result. However, the convenience and rapid turnaround time of oral fluid-based POCTs, their ease of use, and patient preference for noninvasive sample collection may compensate for their slightly lower sensitivity. In sum, these tests could be safely integrated into expanded screening initiatives as first-line screening tests by using downstream blood-based algorithms to detect infections missed by oral fluid tests.
The POCTs that showed promise in individual studies were the Anti-HCV Ab rapid test, SM-HCV Rapid Test, OraQuick HCV Rapid Antibody Test, and Dual Path Platform test. The RDT HCV Tri-Dot also had high accuracy ( Table 1) .
Our meta-analysis is subject to the detection, spectrum, and sampling biases of the original studies. Of the 6 included case-control studies, only 3 (7, 29, 32) explicitly mentioned blinded reading of index test results, suggesting possible detection bias in the remaining studies. This could artificially inflate sensitivity and specificity estimates of the index test. The use of a case-control design also entails an extreme comparison of index tests in healthy and sick persons, suggesting possible spectrum bias.
Our results should be interpreted with some cautions. First, reference standards were found to influence the accuracy of POCTs (19, 20) . When the CDC-recommended ideal reference standard was used, sensitivity and specificity were higher than when an imperfect EIA reference standard was used (20). Only 9 of the included studies (11, 19 -25, 32) used the CDC-recommended reference standard to ascertain true disease status. Misclassification by reference standards is known to influence the measured sensitivity and specificity of index tests (34) . Accuracy estimates from studies that used imperfect reference standards to ascertain true disease status may have been artificially inflated or lowered because of misclassification by the reference standard. A standardization of reference standards is needed for future diagnostic accuracy studies. Second, important factors to consider when interpreting the test results are co-infection status (for example, with HIV or hepatitis B), immune response, and their influence on diagnostic accuracy. In a CDC study (19) , HIV seropositivity was found to have a statistically significant influence on the rate of false-positive results, with an adjusted odds ratio of 11 (CI, 2.53 to 48.17) reported for the Dual Path Platform test and an adjusted odds ratio of 3.95 (CI, 1.53 to 10.24) reported for the Multiplo Rapid HIV/ HCV Antibody Test. This illustrates that both HIV coinfection and initiation of HIV treatment could influence the immune response, thus altering test accuracy. However, only 2 CDC-based implementation studies considered this issue (19, 20) .
Because of the limited data on this issue, future implementation research studies stratified by co-infection (such as with HIV, hepatitis B, or syphilis) are needed to resolve the issue of accuracy in the presence of co-infection. The influence of co-infection (naive or treated) on diagnostic accuracy will be especially relevant as multiplex POCT as- Review Accuracy of Rapid and Point-of-Care Screening Tests for Hepatitis C says that integrate tests for HIV, hepatitis B, and HCV are or will be marketed for point-of-care use and as integrated HIV-sexually transmitted illness screening becomes the global standard of care in the near future. Third, the effect of HCV genotype (genotypes 1 to 6) on diagnostic accuracy is worth further consideration. Genotype explorations were mentioned in a few studies as a potential influence on diagnostic accuracy, but their effect is unknown.
Fourth, at least 4 studies (11, 21, 30, 32) reported receiving industry funding. When comparisons were possible, these studies reported more optimistic estimates of accuracy than did independently funded studies. Although the enforcement of stricter quality standards and the use of particular study designs (such as case-control), select study populations, and the best reference standards may have played a role, these findings need to be independently replicated by non-industry-funded studies.
Fifth, the index tests included in this meta-analysis detected antibodies to HCV and therefore could not detect infection within about 3 months or differentiate between acute and chronic infections (1) . If clinical suspicion of a positive POCT or RDT result is high, further testing would be required. In the case of a possible false-negative result, further screening with another RDT or conventional laboratory-based tests could be considered, depending on available resources. For cases with a preliminary positive result, polymerase chain reaction testing is necessary to identify active infection, as is assessment of liver enzyme levels (35) . More research is needed to determine how to effectively link screening with further linkages and follow-up, especially in hard-to-reach populations and lowresource settings.
Finally, evidence on POCTs will be of greater use to policymakers and guideline developers if outcomes beyond accuracy are documented. These include patient-centered outcomes and operational research outcomes, such as acceptability, preference, feasibility, impact, uptake, time to initiation of confirmatory testing, referrals, and treatment linkages. Accuracy was the sole focus in these studies, so pertinent downstream issues remain unexplored. Similarly, future research on the cost-effectiveness of RDTs or POCTs in different settings, populations, and contexts is warranted to make informed decisions on these tests and on testing strategies.
To our knowledge, this is the first systematic review to synthesize global evidence on POCTs and RDTs that screen for hepatitis C. We used QUADAS-2 and STARD to assess quality and followed PRISMA guidelines in reporting results. Despite our wide search strategy, we could have missed studies in this rapidly growing field and our review may also be subject to publication bias. Although sensitivity analyses that focused on the accuracy of individual tests would have been useful, they could not be done because of a lack of adequate data by test types and the presence of zero cells that precluded pooling of data. The scarcity of studies and data on some tests may also imply that they are not in use anymore.
Both RDTs and POCTs offer many advantages: a fast turnaround time (27, 34) , low psychological stress, declaration of results at the point of care with the potential for affecting clinical management, early detection of undiagnosed cases of hepatitis C (21), relatively easier identification of infection by paramedics or other health professionals (27, 30, 32) , and high intra-and interobserver agreement or concordance (19) . These advantages could be optimized by integrating them into usual care pathways in outpatient clinics, emergency departments, and public health clinics, as has been done with point-of-care HIV screening assays. Given the lack of global evidence, this review comes closer to independently assessing the role of RDTs and POCTs for widespread use in the field by synthesizing all available data on their accuracy and provides further evidence of the benefit of RDTs and POCTs for other developed countries, such as Canada and the United Kingdom, where their use is not yet approved.
We found POCTs of blood (serum, plasma, or whole blood), RDTs of serum or plasma, and POCTs of oral fluid to be accurate and suitable for screening initiatives. In light of their accuracy and the urgent need to increase hepatitis C screening in marginalized and at-risk populations and in endemic HCV settings, these tests could play a substantial role in expanded global screening initiatives, which would eventually impact the control of HCV infection at the population level. 
͑1 Ϫ Specificity͒
This tells us how much more often a positive test result occurs in those with the condition than in those without.
The negative LR is the ratio of the likelihood of a positive test result when the disease is absent to the likelihood when it is present (37):
Specificity
This tells us how much more often a negative test result occurs in those with the condition than in those without.
The diagnostic odds ratio (DOR) is the ratio of the odds of a positive result when the disease is present to the odds of a positive result when the disease is absent (38) 
